Cargando…

Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose

Despite extensive technological advances in recent years, objective and continuous assessment of physiologic measures after vaccination is rarely performed. We conducted a prospective observational study to evaluate short-term self-reported and physiologic reactions to the booster BNT162b2 mRNA (Pfi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mofaz, Merav, Yechezkel, Matan, Guan, Grace, Brandeau, Margaret L., Patalon, Tal, Gazit, Sivan, Yamin, Dan, Shmueli, Erez
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Centers for Disease Control and Prevention 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239876/ https://www.ncbi.nlm.nih.gov/pubmed/35654410 http://dx.doi.org/10.3201/eid2807.212330

Ejemplares similares

Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study
por: Yechezkel, Matan, et al.
Publicado: (2023)

Utilizing wearable sensors for continuous and highly-sensitive monitoring of reactions to the BNT162b2 mRNA COVID-19 vaccine
por: Gepner, Yftach, et al.
Publicado: (2022)

Higher sensitivity monitoring of reactions to COVID-19 vaccination using smartwatches
por: Guan, Grace, et al.
Publicado: (2022)

Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine
por: Patalon, Tal, et al.
Publicado: (2022)

A multi-layer model for the early detection of COVID-19
por: Shmueli, Erez, et al.
Publicado: (2021)

Real-time sensing of war’s effects on wellbeing with smartphones and smartwatches
por: Mofaz, Merav, et al.
Publicado: (2023)

Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents
por: Prunas, Ottavia, et al.
Publicado: (2022)

BNT162b2 mRNA COVID-19 Vaccine Effectiveness in Patients with Coeliac Disease Autoimmunity: Real-World Data from Mass Vaccination Campaign
por: Ben-Tov, Amir, et al.
Publicado: (2023)

Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
por: Prunas, Ottavia, et al.
Publicado: (2021)

Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
por: Prunas, Ottavia, et al.
Publicado: (2022)

Early Oxygen Treatment Measurements Can Predict COVID-19 Mortality: A Preliminary Study
por: Levi, Yosi, et al.
Publicado: (2022)

Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization
por: Chodick, Gabriel, et al.
Publicado: (2021)

Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study
por: Gazit, Sivan, et al.
Publicado: (2022)

Waning of SARS-CoV-2 booster viral-load reduction effectiveness
por: Levine-Tiefenbrun, Matan, et al.
Publicado: (2022)

Hybrid immunity against reinfection with SARS-CoV-2 following a previous SARS-CoV-2 infection and single dose of the BNT162b2 vaccine in children and adolescents: a target trial emulation
por: Gazit, Sivan, et al.
Publicado: (2023)

Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination
por: Grupel, Daniel, et al.
Publicado: (2021)

BNT162b2 vaccination effectively prevents the rapid rise of SARS-CoV-2 variant B.1.1.7 in high-risk populations in Israel
por: Munitz, Ariel, et al.
Publicado: (2021)

Serological response to a third booster dose of BNT162b2 COVID‐19 vaccine among seronegative cancer patients
por: Shmueli, Einat Shacham, et al.
Publicado: (2022)

Early detection of COVID-19 outbreaks using human mobility data
por: Guan, Grace, et al.
Publicado: (2021)

Antibody response to third and fourth BNT162b2 mRNA booster vaccinations in healthcare workers in Tokyo, Japan
por: Sanada, Takahiro, et al.
Publicado: (2023)

Differential effects of COVID-19 lockdowns on well-being: interaction between age, gender and chronotype
por: Oved, Shay, et al.
Publicado: (2021)

Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer
por: Ligumsky, Hagai, et al.
Publicado: (2022)

Transplacental transfer of SARS-CoV-2 antibodies in recovered and BNT162b2-vaccinated patients
por: Treger, Sharon, et al.
Publicado: (2022)

Acute myopericarditis following administration of the BNT162b2 booster vaccine against COVID19
por: Sivan, S.K., et al.
Publicado: (2022)

Immunosuppression as a Hub for SARS-CoV-2 Mutational Drift
por: Shapira, Guy, et al.
Publicado: (2023)

Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
por: Shashar, Moshe, et al.
Publicado: (2022)

Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis
por: Assawasaksakul, Theerada, et al.
Publicado: (2022)

A Data-Driven Strategy for Identifying Individuals Resistant to SARS-CoV-2 Virus under In-Household Exposure
por: Hen Gabzi, Roni, et al.
Publicado: (2022)

BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers
por: Benenson, Shmuel, et al.
Publicado: (2021)

Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod
por: Capuano, Rocco, et al.
Publicado: (2022)

BNT162B2 MRNA BOOSTER VACCINE-RELATED PERICARDITIS: A CASE COMPLICATED BY PERICARDIAL AND PLEURAL EFFUSIONS
por: WHITE, ANESHA, et al.
Publicado: (2022)

BNT162b2 Vaccine Booster and Mortality Due to Covid-19
por: Arbel, Ronen, et al.
Publicado: (2021)

Frosted branch angiitis after booster vaccination with BNT162b2
por: Haas, A.-M., et al.
Publicado: (2023)

Mpox Patient Journey in Israel
por: Patalon, Tal, et al.
Publicado: (2023)

Mpox Infection in a Developed Country: A Case Report
por: Patalon, Tal, et al.
Publicado: (2022)

The effect of a third BNT162b2 vaccine on breakthrough infections in health care workers: a cohort analysis
por: Oster, Yonatan, et al.
Publicado: (2022)

Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2
por: Hertz, Tomer, et al.
Publicado: (2023)

Rapid Progression of Polypoidal Choroidal Vasculopathy following Third BNT162b2 mRNA Vaccination
por: Sasajima, Hirofumi, et al.
Publicado: (2022)

Short-Term Safety of Booster Immunization With BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers
por: Paran, Yael, et al.
Publicado: (2021)

Role of booster with BNT162b2 mRNA in SARS-CoV-2 vaccination in patients with rheumatoid arthritis
por: Benucci, Maurizio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_04vgbqp5rq1k377l38bvi9n34v